Pluripotent Stem Cell Banking Book (2019)

GAiT has written two chapters for ‘Pluripotent stem cell banking for research and specialist applications’ to be published in 2019. These chapters are:

Chapter 10 iPSC Haplobanking for clinical use.

Contents include: iPSC Haplobanking – Rationale for haplobanking iPSCs for clinical use – Sourcing clinical-grade iPSC lines from haplobanks – Generating clinical-grade iPSC lines for deposition in a haplobank – Rederiving research-grade iPSC lines for deposition in clinical haplobanks – HLA polymorphism and consequences for Haplobanking – HLA system; genes and polymorphism – Alloreactivity – HLA typing – Selection of donors for haplobanks – Acquiring samples from donors – Identification of super donors – Beyond HLA – Future steps towards comparability – Animal studies on iPSC transplantation – Human iPSC Transplantation in immune privileged sites – Conclusion – Bibliography

Chapter 25 The Global Alliance for iPSC Therapies

Contents include: Website – Contact email – Introduction containing brief history of development of the network activity – Nature and Source of funding – Key high level aims and format of meetings – Summary description of any steering group or advisory board – Organisation Structure of GAiT – Types of groups/individuals involved any qualifications for membership – Summary of recent meeting topics and any outputs such as reports and publications – Other services provided to, or interactions with, the outside community – Current developments and future plans – Conclusion – Bibliography

More detail on the book (including full table of contents) below:

Pluripotent stem cell banking for research and specialist applications

Guest Editors: Andreas Kurtz (managing editor), Glyn Stacey and Lyn Healy

Publisher: Elsevier

The use of pluripotent stem cell lines has expanded rapidly in a broad range of fields. Quality controlled, ethically sourced and well characterised sources of these cells are vital to ensure that researchers can avoid the pitfalls and wasted resources that come with the distribution of poor quality, cross-contaminated or infected cells. This special issue will address the key factors required to ensure researchers have access to good quality cells and provides reviews of the leading international centres distributing cells under common agreed standards.